Property:Results during intervention
This is a property of type Text.
A
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
After chemotherapy (8 days): significantly better cardiac ejection fraction in sodium selenite arm (mean(SD)= 63(6%)) vs. control arm (69(6%)); p <0.05 +
Asfour et al. (2006): Effect of high-dose sodium selenite therapy on polymorphonuclear leukocyte apoptosis in non-Hodgkin's lymphoma patients +
After chemotherapy (8 days): significant less infections in sodium selenite arm (20%) compared to control arm (67%); p<0.05 +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
NA +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
No difference between treatment arms in the rate of PSA response,
no difference in the median time to PSA response +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
NA +
Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer +
No complete responses were observed,
partial objective response rate was not significantly different, neither was stable disease rate +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
Mean value
After the 1st cycle
Intervention arm (paste): 1.2, intervention arm (tablets): 1.3, placebo arm: 1; p = ns
After 2nd cycle
Intervention arm (paste): 2, intervention arm (tablets): 1.9, placebo arm: 2.2; p = ns
After 3rd cycle
Intervention arm (paste): 2.43, intervention arm (tablets): 3.8, placebo arm: 4.4; p = 0.05 +
Azizi et al. (2015): Efficacy of Topical and Systemic Vitamin E in Preventing Chemotherapy-induced Oral Mucositis +
Number in % with grade 3-4
After 1st cycle
intervention arm (paste): 7.6, intervention arm (tablets): 8.3, placebo arm: 7.6; p = ns
After 2nd cycle
intervention arm (paste): 11.5, intervention arm (tablets): 12.5, placebo arm: 15.3; p = ns
After 3rd cycle
intervention arm (paste): 21.7, intervention arm (tablets): 33.3, placebo arm: 31.8; p = 0.01 +
B
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
DFS for '''any supplementation''' up to 3.5 years after randomization:
HR = 1.65 (95% CI: 1.21, 2.25), i.e. significant difference between intervention and placebo arm (higher risk for intervention arm)
DFS for '''beta-carotene + Vit. E''' up to 3.5 years after randomization:
HR = 1.27 (95% CI: 0.73, 2.21), i.e. no significant difference between intervention and placebo arm
DFS for '''only Vit. E''' up to 3.5 years after randomization:
HR = 1.86 (95% CI: 1.27, 2.72), i.e. significant difference between intervention and placebo arm (higher risk for intervention arm) +
Bairati et al. (2005): A Randomized Trial of Antioxidant Vitamins to Prevent Second Primary Cancers in Head and Neck Cancer Patients +
SPT for '''any supplementation''' up to 3.5 years after randomization:
HR = 2.42 (95% CI: 1.45, 4.04), i.e. significant difference between intervention and placebo arm (higher risk for intervention arm)
SPT for '''beta-carotene + Vit. E''' up to 3.5 years after randomization:
HR = 1.51 (95% CI: 0.58, 3.98), i.e. no significant difference between intervention and placebo arm
SPT for '''only Vit. E''' up to 3.5 years after randomization:
HR = 2.88 (95% CI: 1.56, 5.31), i.e. significant difference between intervention and placebo arm (higher risk for intervention arm)
No influence of smoking status +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
NA +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
Side effects for '''any supplementation''' during radiotherapy (T1):
''All sides'': OR = 0.72 (95% CI: 0.52, 1.02), i.e. no significant difference between intervention and placebo arm
''Larynx, skin, mucosa, pharynx and esophagus'': no significant differences
Side effects for '''beta-carotene + Vit. E''' during radiotherapy (T1):
''All sides'': OR = 0.38 (95% CI: 0.20, 0.74), i.e. significant difference between intervention and placebo arm (lower risk for intervention arm)
''Larynx only'': OR = 0.38 (95% CI: 0.21, 0.71), i.e. significant difference between intervention and placebo arm (lower risk for intervention arm)
''Skin, mucosa, pharynx and esophagus'': no significant differences
Side effects for '''only Vit. E''' during radiotherapy (T1):
''All sides'': OR = 0.92 (95% CI: 0.62, 1.38), i.e. no significant difference between intervention and placebo arm
''Larynx, skin, mucosa, pharynx and esophagus'': no significant differences +
Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients +
NI +
Bairati et al. (2006): Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients +
NA +
Barton et al. (1998): Prospective evaluation of vitamin E for hot flashes in breast cancer survivors +
NA +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
No difference between arms. +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
No difference between arms. +
Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9 +
No difference between arms. +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
No significant differences +
Beer et al. (2007): Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators +
After adjustment for baseline characteristics of hemoglobin and Eastern Cooperative Oncology Group performance status, overall survival showed a promising improvement in intervention arm over the placebo arm with a HR of 0.67 (95% CI, 0.45 to 0.97; p = .04) +